|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | [View online](https://go.iba-worldwide.com/webmail/928513/880095862/bda906319eedee08f16d8fd79de9c189521efddeaec3f0effd54363ab1746ac2) | | |  |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | https://goiba.cdn.salesforce-experience.com/cms/delivery/media/MC4SZV6XPMURCYTFKL7PP6LDW3WE?oid=00D24000000Ysy1EAC&channelId=0ap060000004C9wAAE | | |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | | |  |  |  |  | | --- | --- | --- | --- | | |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | Press Release Regulated Information | **null** | | | |  |  |  | | --- | |  | | | |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | **IBA signs contract with Yale New Haven Health and Hartford HealthCare to install Proteus®ONE proton therapy solution in Connecticut, US**  **Louvain-La-Neuve, Belgium, 2 May 2024**- IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces that it has signed a contract with the Connecticut Proton Therapy Center, a collaboration between Yale New Haven Health, Hartford HealthCare and Proton International, for the installation of a Proteus®ONE[[1]](https://go.iba-worldwide.com/webmail/928513/880095862/bda906319eedee08f16d8fd79de9c189521efddeaec3f0effd54363ab1746ac2" \l "_ftn1" \o ")compact proton therapy system. The contract includes a multi-year operation and maintenance agreement, and it is expected that the center will start treating patients in the spring of 2026. The first downpayment has been received.  The Connecticut Proton Therapy Center will be the first of its kind in the state, and located in Wallingford, Connecticut. Proton therapy treatments will be provided by physicians affiliated with the Yale School of Medicine, the Yale New Haven Smilow Cancer Hospital, and Yale Cancer Center, which is a National Cancer Institute-designated (NCI) Comprehensive Cancer Center, and the Harford HealthCare Cancer Institute.  IBA’s Proteus®ONE, as the only user-centric compact Imaged Guided Intensity Modulated Proton Therapy solution, includes an isocentric Cone Beam Computed Tomography (CBCT) system and an open gantry enabling high-quality treatments with optimized patient throughput and excellent user and patient experience.  The typical end-user price for a Proteus®ONE system with a multi-year maintenance contract ranges between 40-50 million US dollars.  **Olivier Legrain, Chief Executive Officer of IBA, commented:***“We are very proud to have signed this contract, which, once installed, will provide patients in Connecticut with access to cutting-edge proton therapy technology. We look forward to working with Yale New Haven Health and Hartford HealthCare Corporation as they seek to deliver world-class cancer care to patients.”*  **Peter Glazer, MD, PhD, chief of Radiation Oncology, Yale New Haven Hospital and chair, Therapeutic Radiology, Yale School of Medicine added:***“We are pleased to have secured IBA as the technology leader to move forward with our proton therapy initiative, completing our panel of comprehensive cancer care. Our oncology experts are excited to provide this life changing treatment to our patients.”*  **Andrew Salner, M.D., Director of the Hartford HealthCare Cancer Institute, stated:***“We are proud to be part of the first proton therapy project in the State of Connecticut and look forward to seeing the benefit to our community. Working with IBA will enable us to offer patients with the latest and most advanced proton therapy technology.”*  **Chris Chandler, Chief Executive Officer of Proton International LLV., said:***“We are honored to assist the Connecticut Proton Therapy Center for the design and development of the facility which will be the first proton cancer treatment center in the State of Connecticut. At the moment patients have to travel out of state, the nearest locations being in New York City and Boston, to receive this advanced option for cancer treatment.”*    [[1]](https://go.iba-worldwide.com/webmail/928513/880095862/bda906319eedee08f16d8fd79de9c189521efddeaec3f0effd54363ab1746ac2" \l "_ftnref1" \o ") Proteus®ONE is the brand name of Proteus®235 | | | | |  |  | | --- | --- | | |  | | --- | | **About IBA** IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.  IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).  More information can be found at: [www.iba-worldwide.com](https://go.iba-worldwide.com/e/928513/2024-05-02/bjrm68/880095862/h/ilImj11OJMhug-PcyE_5fQ4tkMWwn4-Tpy8Lb_oj4t0)  **About Hartford HealthCare Corporation (HHC)** HHC is a nonstock corporation existing under the laws of the State.  HHC was organized in 1985 and is the controlling entity of a series of affiliated entities that own and operate a health care system that offers a broad range of health care services to most residents of the State and to residents of more than two dozen towns and cities in Massachusetts and Rhode Island, through a network of seven hospitals, a behavioral health network, a multispecialty physician group, a variety of senior care facilities, home care services, and a comprehensive physical therapy and rehabilitation network, among other services.   HHC is governed by a 16-member Board of Directors.  Additional information about HHC can be found on its website: <https://go.iba-worldwide.com/e/928513/about-us/bjrm6c/880095862/h/ilImj11OJMhug-PcyE_5fQ4tkMWwn4-Tpy8Lb_oj4t0>.  **About Yale New Haven Health Services Corporation (YNHHS)** YNHHS is a nonstock corporation existing under the laws of the State.  YNHHS was formed in 1996 to enhance the quality and scope of healthcare services of residents of the State and now serves the State as well as eastern New York, southern Rhode Island and beyond.  YNHHS includes five hospitals as well as other operating entities providing health care services across the health care continuum and has a formal affiliation agreement with Yale University School of Medicine (“YSM”) to support patient care, medical education and clinical research.  YNHHS is also affiliated with YSM’s clinical practice – Yale Medicine – which is the largest academic multispecialty practice in New England, with more than 1,500 physicians practicing in over 160 specialties.  YNHHS is governed by a 18-member Board of Trustees.  Additional information about YNHHS can be found on its website: <https://go.iba-worldwide.com/e/928513/about/bjrm6g/880095862/h/ilImj11OJMhug-PcyE_5fQ4tkMWwn4-Tpy8Lb_oj4t0>.  **About Proton International** Proton International, [www.protonintl.com](https://go.iba-worldwide.com/e/928513/2024-05-02/bjrm6k/880095862/h/ilImj11OJMhug-PcyE_5fQ4tkMWwn4-Tpy8Lb_oj4t0), has an experienced team dedicated to bringing proton therapy to patients. The company works with hospitals and physician groups to develop one- and two-room proton therapy facilities on a turnkey basis. The PI team has developed and operated multiple centers and is currently active on several projects. | | | | |  |  | | --- | --- | | |  | | --- | | Proton International completed proton centers at William Beaumont Hospital in Royal Oak, Michigan University, Medical Center in Groningen, The Netherlands, Delray Beach, Florida; and Proton International Arkansas LLC where the centers are currently treating patients. The company has several additional centers under design and construction. PI’s business model ensures that projects are completed on time, on budget, and within the scope and needs of the institution. Services include business planning, organizational structure, financing, building design and construction, installation and commissioning, equipment, staff training, and more.  **For further information, please contact:**  **IBA** **Soumya Chandramouli** Chief Financial Officer +32 10 475 890 Investorrelations@iba-group.com   **Olivier Lechien** Corporate Communication Director +32 10 475 890 communication@iba-group.com  **For media and investor enquiries:** Consilium Strategic Communications Amber Fennell, Angela Gray,  Lucy Featherstone +44 (0) 20 3709 5700 IBA@consilium-comms.com | | | |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | | |  |  |  |  | | --- | --- | --- | --- | | |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | Communiqué de presse Information réglementée | **null** | | | |  |  |  | | --- | |  | | | |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | **IBA signe un contrat avec Yale New Haven Health et Hartford HealthCare pour l’installation d’une solution de protonthérapie Proteus®ONE dans le Connecticut, aux États-Unis**  **Louvain-la-Neuve, Belgique, le 2 mai 2024**- IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial de la technologie d’accélération de particules, annonce aujourd'hui avoir signé un contrat avec le Connecticut Proton Therapy Center, une collaboration entre Yale New Haven Health, Hartford HealthCare et Proton International, pour l'installation d'un système compact de protonthérapie Proteus®ONE[[1]](https://go.iba-worldwide.com/webmail/928513/880095862/bda906319eedee08f16d8fd79de9c189521efddeaec3f0effd54363ab1746ac2" \l "_ftn1" \o "). Le contrat comprend un accord d’exploitation et de maintenance de plusieurs années. Le centre devrait commencer à traiter ses premiers patients au printemps 2026. Un premier paiement a été reçu.  Le Connecticut Proton Therapy Center sera le premier centre de protonthérapie dans l'État et sera situé à Wallingford, Connecticut. Les traitements seront administrés par des médecins affiliés à la Yale School of Medicine, au Yale New Haven Smilow Cancer Hospital et au Yale Cancer Center, qui est un centre de soins oncologiques complets désigné par le National Cancer Institute (NCI), et l'Institut du cancer de Harford HealthCare.  Le système Proteus®ONE d'IBA est la seule solution compacte de protonthérapie à intensité modulée par guidée par l’image. Elle comprend un système de tomographie par faisceau conique (Cone Beam Computed Tomography (CBCT)) à l’isocentre et un portique ouvert qui permet des traitements de haute qualité avec un flux de patients optimisé et une utilisation plus adaptée pour les équipes médicales et les patients.  Le prix usuel d’un système Proteus®ONE avec un contrat de maintenance pluriannuel varie entre USD 40 et 50 millions.  **Olivier Legrain, Chief Executive Officer d’IBA, indique :***« Nous sommes très fiers d'avoir signé ce contrat qui, une fois installé, offrira aux patients du Connecticut un accès à la technologie de pointe que constitue la protonthérapie. Nous sommes impatients de travailler avec Yale New Haven Health et Hartford HealthCare Corporation pour réaliser leur ambition de fournir des soins contre le cancer de classe mondiale aux patients. »*  **Peter Glazer, MD, PhD, chief of Radiation Oncology, Yale New Haven Hospital and chair, Therapeutic Radiology, Yale School of Medicine ajoute***: « Nous sommes heureux d'avoir signé avec IBA qui est le leader technologique pour faire avancer notre initiative de protonthérapie, afin de compléter notre panel de soins contre le cancer. Nos experts en oncologie sont ravis de fournir ce traitement qui permet de changer la vie de nos patients. »*  **Andrew Salner, M.D.,Director of the Hartford HealthCare Cancer Institute, déclare***: « Nous sommes fiers de faire partie du premier projet de protonthérapie dans l'État du Connecticut et nous attendons avec impatience de voir les bénéfices pour notre communauté. Travailler avec IBA nous permettra d'offrir aux patients la technologie de protonthérapie la plus récente et la plus avancée. »*  [[1]](https://go.iba-worldwide.com/webmail/928513/880095862/bda906319eedee08f16d8fd79de9c189521efddeaec3f0effd54363ab1746ac2#_ftnref1) Proteus®ONE est une marque de Proteus 235. | | | | |  |  | | --- | --- | | |  | | --- | | **Chris Chandler, Chief Executive Officer of Proton International LLV,commente***: « Nous sommes honorés de soutenir le Connecticut Proton Therapy Center pour la conception et le développement de l'installation qui sera le premier centre de traitement du cancer par protons dans l'État du Connecticut. Pour le moment, les patients doivent voyager hors de l'État, les centres les plus proches étant à New York et à Boston, pour recevoir cette option avancée de traitement du cancer. »*   \*\*\*FIN\*\*\*   **À propos d’IBA** IBA (Ion Beam Applications S.A.) est le leader mondial dans la technologie d’accélération de particules. La société est le principal fournisseur d’équipements et de services dans le domaine de la protonthérapie, considérée comme la forme la plus avancée de radiothérapie disponible aujourd'hui. IBA est par ailleurs un acteur de premier plan dans les domaines de la stérilisation industrielle, de la radiopharmacie et de la dosimétrie. L’entreprise, basée à Louvain-la-Neuve, en Belgique, emploie environ 2000 personnes dans le monde. IBA est une entreprise certifiée B Corporation (B Corp) qui répond aux plus hauts standards de performance sociale et environnementale. La société est cotée à la bourse paneuropéenne EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). Pour plus d’informations : [www.iba-worldwide.com](https://go.iba-worldwide.com/e/928513/2024-05-02/bjrm68/880095862/h/ilImj11OJMhug-PcyE_5fQ4tkMWwn4-Tpy8Lb_oj4t0)  **À propos d'Hartford HealthCare Corporation (HHC) :** HHC est une société sans capital-actions existant sous les lois de l'État. Organisée en 1985, HHC est l'entité contrôlante d'une série d'entités affiliées qui possèdent et exploitent un système de soins de santé offrant une large gamme de services de santé à la plupart des résidents de l'État ainsi qu'aux résidents de plus de deux douzaines de villes et de communes dans le Massachusetts et Rhode Island, à travers un réseau de sept hôpitaux, un réseau de santé comportementale, un groupe de médecins multi spécialités, une variété d'établissements de soins pour seniors, des services de soins à domicile, et un réseau complet de thérapie physique et de réadaptation, parmi d'autres services. HHC est dirigée par un conseil d'administration de 16 membres. Des informations supplémentaires sur HHC peuvent être trouvées sur son site web : <https://go.iba-worldwide.com/e/928513/about-us/bjrm6c/880095862/h/ilImj11OJMhug-PcyE_5fQ4tkMWwn4-Tpy8Lb_oj4t0>.  **À propos de Yale New Haven Health Services Corporation (YNHHS)** YNHHS est une société sans capital-actions existant sous les lois de l'État. Formée en 1996 pour améliorer la qualité et l'étendue des services de soins de santé pour les résidents de l'État, YNHHS dessert maintenant l'État ainsi que l'est de New York, le sud de Rhode Island et au-delà. YNHHS comprend cinq hôpitaux ainsi que d'autres entités opérationnelles fournissant des services de soins de santé à travers le continuum des soins de santé et a un accord d'affiliation formel avec l'École de Médecine de l'Université Yale (« YSM ») pour soutenir les soins aux patients, l'éducation médicale et la recherche clinique. YNHHS est également affiliée à la pratique clinique de YSM – Yale Medicine – qui est la plus grande pratique multispecialité académique en Nouvelle-Angleterre, avec plus de 1 500 médecins pratiquant dans plus de 160 spécialités. YNHHS est dirigée par un conseil de fiduciaires de 18 membres. Des informations supplémentaires sur YNHHS peuvent être trouvées sur son site web :  https://go.iba-worldwide.com/e/928513/about-/bjrm6n/880095862/h/ilImj11OJMhug-PcyE\_5fQ4tkMWwn4-Tpy8Lb\_oj4t0   **À propos de Proton International** Proton International, www.protonintl.com, dispose d'une équipe expérimentée dédiée à l'apport de la thérapie par protons aux patients. La société collabore avec des hôpitaux et des groupes de médecins pour développer des installations de thérapie par protons d'une ou deux salles sur une base clé en main. L'équipe de PI a développé et géré plusieurs centres et est actuellement active sur plusieurs projets.  Proton International a achevé des centres de protons à l'Hôpital William Beaumont à Royal Oak, à l'Université du Michigan, au Centre Médical de Groningen, aux Pays-Bas, à Delray Beach, en Floride; et Proton International Arkansas LLC où les centres traitent actuellement des patients. La société a plusieurs autres centres en conception et en construction. Le modèle commercial de PI garantit que les projets sont achevés à temps, dans les limites du budget, et conformément à la portée et aux besoins de l'institution. Les services comprennent la planification d'entreprise, la structure organisationnelle, le financement, la conception et la construction de bâtiments, l'installation et la mise en service, l'équipement, la formation du personnel, et plus encore. | | | | |  |  | | --- | --- | | |  | | --- | | **Pour plus d'informations, contacter** : **IBA** **Soumya Chandramouli** Chief Financial Officer +32 10 475 890 Investorrelations@iba-group.com  **Olivier Lechien** Corporate Communication Director +32 10 475 890 communication@iba-group.com | | | |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | | |  |  |  |  | | --- | --- | --- | --- | | |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | **null** | **Logo Certified 55px** | | | |  |  |  | | --- | |  | | | |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | ION BEAM APPLICATIONS SA Chemin du Cyclotron 3 Ottignies-Louvain-la-Neuve, 1348 Belgium  Tel.: + 32 10 47 58 1 | Fax: + 32 10 47 58 10 E-mail: info-worldwide@iba-group.com | www.iba-worldwide.com RPM Brabant wallon | VAT: BE 0428 750 985 | | | |  |  | | --- | --- | | |  | | --- | | [https://goiba.cdn.salesforce-experience.com/cms/delivery/media/MCR7KMV7XWUVBEPETX55NRSOLQNI?oid=00D24000000Ysy1EAC&channelId=0ap060000004C9wAAE](https://go.iba-worldwide.com/e/928513/company-iba-/bjrm6r/880095862/h/ilImj11OJMhug-PcyE_5fQ4tkMWwn4-Tpy8Lb_oj4t0)  [https://goiba.cdn.salesforce-experience.com/cms/delivery/media/MCDZHDVFFXVZEO3FTRE54HIRMOBE?oid=00D24000000Ysy1EAC&channelId=0ap060000004C9wAAE](https://go.iba-worldwide.com/e/928513/ibaworldwide-/bjrm6v/880095862/h/ilImj11OJMhug-PcyE_5fQ4tkMWwn4-Tpy8Lb_oj4t0)  [https://goiba.cdn.salesforce-experience.com/cms/delivery/media/MCMEWV5VN6PZGKFDACUQWX3POIYA?oid=00D24000000Ysy1EAC&channelId=0ap060000004C9wAAE](https://go.iba-worldwide.com/e/928513/ibaworldwide/bjrm6y/880095862/h/ilImj11OJMhug-PcyE_5fQ4tkMWwn4-Tpy8Lb_oj4t0)  [https://goiba.cdn.salesforce-experience.com/cms/delivery/media/MCRJQ4TQUCGNGMJKEI3OAC4CRHA4?oid=00D24000000Ysy1EAC&channelId=0ap060000004C9wAAE](https://go.iba-worldwide.com/e/928513/user-ibagroup/bjrm72/880095862/h/ilImj11OJMhug-PcyE_5fQ4tkMWwn4-Tpy8Lb_oj4t0)  [https://goiba.cdn.salesforce-experience.com/cms/delivery/media/MCDAT3OXATTZCAFCQLNA4PWO37JA?oid=00D24000000Ysy1EAC&channelId=0ap060000004C9wAAE](https://go.iba-worldwide.com/e/928513/ibaworldwide--hl-fr/bjrm75/880095862/h/ilImj11OJMhug-PcyE_5fQ4tkMWwn4-Tpy8Lb_oj4t0) | | | |  | | --- | | Copyright © IBA SA 2024. All rights reserved You can [update your preferences](https://go.iba-worldwide.com/e/928513/y6wpju98xQCRxB1x9R3GRwSTC4-753/bjrm78/880095862/h/ilImj11OJMhug-PcyE_5fQ4tkMWwn4-Tpy8Lb_oj4t0) or [unsubscribe](https://go.iba-worldwide.com/unsubscribeConfirm/928513/bda906319eedee08f16d8fd79de9c189521efddeaec3f0effd54363ab1746ac2/880095862) from all IBA Communications. | | | | |